Best OpenEvidence Alternatives in 2026: 7 Clinical AI Answer Engines and Decision-Support Tools

Glass Health combines ambient scribing and clinical decision support in one product. UpToDate may be worth reviewing when your organization already uses UpToDate as part of its clinical reference workflow. Elsevier says ClinicalKey includes EHR integration and AI-powered answers sourced from trusted, evidence-based content. The DynaMed homepage highlights Dyna AI, Specialties, Alerts, Drug Resources, and Chemo Regimens. AMBOSS promotes AI Mode within its medical knowledge platform for doctors and students. Dr.Oracle describes itself as “The World’s Most Powerful Medical Artificial Intelligence Platform.”

DoxGPT remains in this guide as a separate diligence track, but this revision does not include a sourced product summary for it because the active comparison is limited to entries supported by currently verifiable public materials.

Glass Health

What it is: Glass Health combines ambient scribing and clinical decision support. Its product pages also describe Ambient CDS, Consult (Clinical Reference Q&A), Differential Diagnosis, Chart Summarization, and documentation workflows.

Best for: Clinicians, practice leaders, and IT teams that want to evaluate documentation workflow and clinical support together instead of in separate product tracks.

Pricing: Glass Health lists Lite (free), Starter ($20/mo), Pro ($90/mo), and Max ($200/mo) on the pricing page.

EHR integrations: Glass’s EHR integration page says the platform integrates into existing EHR workflows using SMART on FHIR technology and pulls patient data into the AI platform. Glass currently supports Epic, eClinicalWorks, athenahealth, and Elation in read-only workflows. The current Glass implementation pattern is SMART on FHIR Backend Services using the client_credentials grant and system/*.read scope. For athenahealth, eClinicalWorks, and Elation, start with a direct SMART on FHIR review with Glass and your EHR team.

Strengths: The clearest reason to evaluate Glass in an OpenEvidence comparison is that Glass changes the shape of the buying conversation. A lot of “clinical AI answer engine” evaluations begin and end with one question: can the product answer medical questions well enough to deserve a place in daily workflow? Glass matters because it adds a second question that many teams care about just as much: can the same product help with the documentation work happening before, during, and after the clinical question arises? If the answer you need sits in the middle of a visit, a note, a chart review, and a follow-up workflow, the value of evaluating ambient scribing and clinical decision support together becomes obvious.

Glass supports that broader workflow in concrete terms. Glass combines ambient scribing with clinical decision support, clinical reference Q&A, differential diagnosis, chart summarization, real-time audio analysis, diagnostic insights, an evolving differential diagnosis, suggested history questions, suggested physical maneuvers, and preliminary next steps. Taken together, Glass is more than a static lookup tool. It gives clinicians a workflow that can capture the visit, summarize context, and surface decision-support help within the same product evaluation.

That broader workflow is especially useful for organizations that do not want separate committees evaluating separate tools for separate pieces of the same encounter. A clinician champion may care about note quality and time spent after clinic. An operations lead may care about rollout, training, and pricing clarity. An IT or informatics lead may care about integration pattern, data access, and implementation scope. Glass gives those groups one product to review together. Even if a team ultimately decides to phase the rollout, starting from one cross-functional workflow can make evaluation more coherent.

Public pricing also helps early-stage planning. A free Lite tier gives an individual clinician or small pilot group a simple way to test fit. Starter, Pro, and Max give practices a visible pricing ladder they can use for rough budget planning before a formal enterprise conversation.

Weaknesses: The central tradeoff is the current READ-ONLY integration posture. If your organization requires write-back, in-chart signing, ordering actions, or a deeper in-EHR execution model on day one, validate present-day workflow fit directly with Glass before rollout. Teams should also be deliberate about pilot design. Because Glass spans documentation and clinical support, a weak pilot can under-test the product by looking at only one slice of the workflow.

How to enable Glass

A practical Glass rollout usually follows a straightforward sequence:

1. Start with the right plan for the pilot. Lite is the easiest entry point for individual testing. Starter, Pro, and Max make more sense when the pilot already has a defined team, department, or expansion path.
2. Confirm the supported EHR environment. Glass currently supports Epic, eClinicalWorks, athenahealth, and Elation in read-only workflows.
3. Set up SMART on FHIR Backend Services. The key technical pieces are the Backend Services pattern, the client_credentials grant, and the system/*.read scope.
4. Define the read-only context you need. Before the pilot begins, decide which patient-context workflows matter most: ambient documentation, chart review, summarization, consult-style Q&A, or Ambient CDS support during the encounter.
5. Coordinate implementation directly with Glass. For Epic, that means aligning registration and workflow validation with your Epic team and Glass.
6. Pilot the complete workflow, not just access. A successful test should cover how clinicians use the product from conversation capture to note generation to chart summarization to clinical-support prompts, not just whether data can be reached.
7. Expand only after workflow validation.

Switch from OpenEvidence if... you want to compare a product that combines ambient scribing and clinical decision support in one workflow.

UpToDate

What it is: This slot relies on the public UpToDate homepage, so the summary here is intentionally limited. If your organization already uses UpToDate, use that existing reference workflow as a starting point and confirm current product naming, pricing, and technical details directly with the vendor.

Best for: Teams that already have an UpToDate-centered clinical reference process and want to use that installed workflow as the starting point for diligence.

Pricing: Confirm current pricing directly with UpToDate.

Strengths: The practical appeal here is continuity. If clinicians, library teams, and medical leadership already rely on UpToDate, starting from that existing workflow can simplify the internal conversation.

Weaknesses: Because this guide is intentionally limited to source-backed public wording, the public homepage is not enough to answer product-naming, packaging, provenance, administrative-control, security, or deployment questions.

Switch from OpenEvidence if... you want to start from an existing UpToDate reference workflow and confirm current product naming, pricing, and technical details directly with the vendor.

ClinicalKey AI

What it is: Elsevier describes ClinicalKey within its evidence-based decision-support portfolio. Clinicians can “Find answers faster with ClinicalKey AI Powered by responsible AI... sourced from trusted, evidence-based content” ( ClinicalKey).

Best for: Health systems, groups, and library teams that already buy into Elsevier content and want to review AI answers inside that ecosystem.

Pricing: Contact us ( ClinicalKey).

Strengths: ClinicalKey is a sensible shortlist entry when the buying conversation already runs through Elsevier relationships and content strategy.

Weaknesses: Buyers should still ask Elsevier to show the specific package, implementation path, and administrative controls that would apply in their environment.

Switch from OpenEvidence if... your institution already uses Elsevier content heavily and you want to compare that workflow directly against OpenEvidence and Glass.

DynaMed

What it is: For this slot, the cited public source is the DynaMed homepage which highlights Dyna AI, Specialties, Alerts, Drug Resources, and Chemo Regimens.

Best for: Buyers who want to include DynaMed on the shortlist and review how Dyna AI and related knowledge resources fit their clinical workflow.

Pricing: Use EBSCO’s public DynaMed materials to confirm current packaging and pricing details.

Strengths: DynaMed is worth evaluating when the organization wants a reference-oriented option that publicly emphasizes not only AI but also adjacent knowledge resources such as alerts, drug resources, and chemo regimens.

Weaknesses: Because this article is intentionally limited to source-backed public wording, buyers should ask EBSCO to show the exact package, answer workflow, security posture, and deployment approach that would apply to their clinicians.

Switch from OpenEvidence if... you want DynaMed on the shortlist and plan to evaluate Dyna AI and related resources directly from EBSCO’s current public materials.

AMBOSS AI Mode

What it is: AMBOSS describes itself as a medical knowledge platform for doctors and students and promotes AI Mode, with public language that the platform is “enhanced by the latest AI technology” ( AMBOSS).

Best for: Teaching hospitals, residency-heavy groups, and clinicians who want to review AI Mode inside a broader knowledge platform.

Pricing: AMBOSS promotes a 5-day free trial and a public Pricing path on its site ( AMBOSS).

Strengths: AMBOSS is especially relevant where learning and point-of-care support overlap.

Weaknesses: Buyers should still verify which package includes the exact workflow they want, how institutional access is handled, and what deployment model is appropriate for their setting.

Switch from OpenEvidence if... your team wants to compare OpenEvidence with a medical knowledge platform that publicly promotes AI Mode and a free trial.

DoxGPT

This version does not include a sourced product summary for DoxGPT. That does not mean DoxGPT cannot belong on an internal shortlist; it means this page is limited to products supported by currently verifiable public materials for the claims made here.

If DoxGPT is on your internal list, treat it as a separate diligence track and request written details on pricing, provenance, security, data handling, and deployment before making a decision.

Dr.Oracle

What it is: The Dr.Oracle homepage describes the product as “The World’s Most Powerful Medical Artificial Intelligence Platform.”

Best for: Buyers who want another medical-AI platform on the shortlist and are comfortable validating details directly with the vendor.

Pricing: Confirm directly with Dr.Oracle.

Strengths: Dr.Oracle is a reasonable vendor to review if your evaluation process is broad and you want to look beyond the largest incumbent knowledge brands.

Weaknesses: Before purchase, confirm pricing, provenance, security, and deployment details directly with Dr.Oracle.

Switch from OpenEvidence if... you want another medical-AI platform on the shortlist and are prepared to validate the details directly with the vendor.